Renal Osteodystrophy

Aka: Renal Osteodystrophy, Chronic Kidney Disease related Bone Disease, Calcium and Phophorus Metabolism in Chronic Kidney Disease

advertisement

II. Indications

  1. Secondary Hyperparathyroidism in Chronic Kidney Disease Stage 5

III. Pathophysiology

  1. Primary: Decreased Glomerular Filtration Rate
    1. Hypocalcemia
      1. Decreased Vitamin D activity and deficiency with decreased Calcium absorption
    2. Hyperphosphatemia
      1. Phosphate retention
  2. Secondary Hyperparathyroidism
    1. Contrast with Primary Hyperparathyroidism (where Calcium is increased and phosphate low)
    2. Results in increased Osteoclast activity and increased bone turnover
  3. Ultimate bone impacts
    1. Oseteomalacia
    2. Osteitis Fibrosa Cystica

IV. Labs

  1. Serum Phosphate
  2. Serum Calcium
  3. Parathyroid Hormone
  4. 25-Hydroxyvitamin D
    1. Also increases PTH
    2. Replace if <30 ng/ml

V. Management: Parathyroid Hormone (PTH) target

  1. Target Parathyroid Hormone
    1. Stage 3: 35-70 pg/ml
    2. Stage 4: 70-110 pg/ml
    3. Stage 5: 150-300 pg/ml
  2. Initial Steps: Measures to suppress PTH Secretion
    1. Treat Hyperphosphatemia
    2. Give hormonally active Vitamin D (Calcitriol)
    3. Give Vitamin D Analogs (e.g. Zemplar)
  3. Persistent rise in PTH despite initial steps
    1. 25-OH-Vitamin D <30 ng/ml
      1. Replace with Ergocalciferol or Cholecalciferol
    2. 25-OH-Vitamin D >30 ng/ml: Give Cacitriol (if Calcium <9.5, Phosphorus <5.5, CaxPO4 <55)
      1. PTH 70-300 (ckd3) or 110-300 (ckd4) Calcitriol 0.25 mcg/day
      2. PTH 300-600: Calcitriol 0.5 to 1.0 mcg/day
      3. PTH 600-1000: Calcitriol 1 to 2 mcg/day
  4. Persistent rise despite above in Dialysis patients
    1. Calcimimetic: Cinacalcet (Sensipar) or Etelcalcetide (Parsabiv)
      1. Suppresses PTH by increasing Parathyroid Gland's Calcium-sensing Receptor Sensitivity
    2. Parathyroidectomy
      1. May be indicated in Hemodialysis patients with secondary Hyperparathyroidism
      2. Improves Hypercalcemia and Hyperphosphatemia
      3. Improves Bone Mineral Density
      4. Improves quality of life and decreases mortality
      5. Lau (2018) Clin J Am Soc Nephrol 13(6): 952-61 [PubMed]

VI. Management: Phosphate

  1. Serum Phosphorus Target
    1. Stage 3-4 CKD: 2.7 to 4.6 mg/dl
    2. Stage 5 CKD: 3.5 to 5.5 mg/dl
  2. Dietary phosphate restriction
    1. Limit phosphate to 800-1000 mg/day
    2. Avoid highly processed foods, fast foods and dark colas
    3. Indication
      1. PTH increased
      2. Phosphate levels >4.6 mg/dl
  3. Phosphate Binders (Hemodialysis patients)
    1. Calcium Carbonate (Tums, 40% elemental Calcium)
    2. Sevelamer carbonate (Renvela)
    3. Calcium Acetate (Phoslo, 21% elemental Calcium)
    4. Lanthanum Carbonate (Fosrenol)
  4. Avoid
    1. Calcium Citrate (citracal)
    2. Aluminum based binding agents (due to aluminum deposition in bone)

VII. Management: Calcium

  1. Serum Calcium and Serum Phosphate Target
    1. Keep Ca x PO4 <55
  2. Keep total Calcium 8.4 to 9.5
    1. Maximum Dietary Calcium 2000 mg/day (including Calcium based binders)
  3. Total Serum Calcium <8.4 (or PTH>55)
    1. Oral Calcium supplement
    2. Oral Vitamin D
    3. Calcitrol (Rocaltrol) 25 mcg every other day
  4. Total Serum Calcium >9.5 or PTH below goal
    1. Discontinue Calcium Supplementation
    2. Avoid Calcium-based Phosphate Binders
    3. Avoid Vitamin D

VIII. Complications

  1. Osteitis Fibrosa Cystica

IX. References

  1. Sell (2022) Am Fam Physician 105(3): 289-98 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Renal Osteodystrophy." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Related Topics in Rheumatology

advertisement